# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Fannie Lou Hamer (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML031-SYN
- Date: 2026-05-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorraine Batiste-Hill, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week review: blood pressure, kidney function and potassium after the new medicines, lipids, retinal photographs, and benefits. **S**

## History of present illness

Mrs. Hamer returns six weeks after starting amlodipine-benazepril and dapagliflozin. Her home readings have come down to an average of 138/86. She has had no dizziness, cough, ankle swelling or genital itching. The potassium and creatinine check planned one to two weeks after the new medicines did not happen: the neighbor who was to drive her could not, the health center's van did not run to her road that week, and she did not want to ask again. SNAP has been approved; the energy assistance is pending. She went to the first diabetes class. She agreed today to blood tests and to retinal photographs once the camera was explained, and asked to see the pictures. **S**

| Element | Detail |
|---|---|
| Home blood pressure | Average 138/86 |
| Missed check | Potassium and creatinine not done at one to two weeks: no ride |
| Side effects | None |
| Benefits | SNAP approved; energy assistance pending |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No dizziness or fainting |
| Respiratory | Negative | No cough |
| Cardiovascular | Negative | No ankle swelling |
| Genitourinary | Negative | No burning or genital itching |
| Eyes | Positive | Reduced vision in the left eye, unchanged |

5 systems reviewed. **S**

## Current medications

- Metformin extended-release 500 mg oral tablet, one tablet with the evening meal for one week, then two tablets with the evening meal **S**
- Atorvastatin 40 mg oral tablet, one tablet daily **S**
- Amlodipine 5 mg and benazepril 20 mg combined oral capsule, one capsule daily **S**
- Dapagliflozin 10 mg oral tablet, one tablet daily; stop on days of vomiting, diarrhea or not eating, and before surgery **S**

## Allergies

- No known allergy **S**

## Objective

BP 136/84 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 91.8 kg; BMI 34.6 kg/m². All vital signs are synthetic.

Sodium: 140 mmol/L; Potassium: 4.7 mmol/L; Creatinine: 1.04 mg/dL; eGFR (CKD-EPI 2021): 66 mL/min/1.73 m² (low); Total cholesterol: 154 mg/dL; LDL cholesterol: 80 mg/dL; HDL cholesterol: 46 mg/dL (low); Triglycerides: 142 mg/dL; ALT: 26 U/L. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.3 mmol/L at baseline, 4.7 mmol/L at this visit **S**
- Creatinine: 0.96 mg/dL at baseline, 1.04 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 73 mL/min/1.73 m² (low) at baseline, 66 mL/min/1.73 m² (low) at this visit **S**
- Total cholesterol: 228 mg/dL (high) at baseline, 154 mg/dL at this visit **S**
- LDL cholesterol: 146 mg/dL (high) at baseline, 80 mg/dL at this visit **S**
- HDL cholesterol: 44 mg/dL (low) at baseline, 46 mg/dL (low) at this visit **S**
- Triglycerides: 190 mg/dL (high) at baseline, 142 mg/dL at this visit **S**
- ALT: 24 U/L at baseline, 26 U/L at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| Consent and chaperone | Blood draw, retinal photographs and examination explained and agreed; female nurse present |
| General | Well; blood pressure 136/84, pulse 78; weight 91.8 kg |
| Cardiovascular | Regular rhythm; no ankle swelling |
| Eyes | Retinal photographs without dilating drops: no diabetic retinopathy in either eye; old scarring in the left eye consistent with her past injury |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hypertension with chronic kidney disease** (I12.9). Improving, not yet at goal; the medicines have had six weeks. **S**
   - Continue amlodipine-benazepril.
   - Community health worker to collect home readings by phone in four weeks; increase the dose if the average stays above 130/80.
2. **Chronic kidney disease G2 A2** (N18.2). Potassium 4.7 mmol/L and creatinine 1.04 mg/dL (eGFR 66, a fall of under 10% from 73): the expected small change after starting benazepril and dapagliflozin, not harm. **S**
   - Continue both medicines.
   - Future checks on her clinic days, with rides arranged in advance, or a home blood draw.
3. **Hyperlipidemia** (E78.5). LDL 80 mg/dL on atorvastatin 40 mg, from 146; goal below 70. ALT 26 U/L. She did not want another pill now. **S**
   - Continue atorvastatin 40 mg; revisit a higher dose or ezetimibe at the yearly panel, her choice.
4. **Type 2 diabetes** (E11.65). No diabetic retinopathy; first diabetes class attended. **S**
   - Retinal photographs again in one to two years.
   - Continue classes.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Consent and chaperone for every examination, test and procedure | Every visit | Completed today | Blood draw, photographs and examination explained and agreed; she asked to see her retinal pictures and they were shown to her |
| Examination | Clinic blood pressure (seated, two readings, large cuff) | Every visit | Completed today | 136/84 |
| Self-management | Home blood pressure readings | Seven days to confirm the diagnosis; then twice a week, and daily for a week after any change | Completed today | Average 138/86 |
| Examination | Weight and BMI | Every visit | Completed today | 91.8 kg |
| Laboratory | Potassium, creatinine and eGFR | One to two weeks after starting an ACE inhibitor, then every 6 months (more often with changes) | Deferred | Missed: the check planned one to two weeks after starting benazepril and dapagliflozin was not done because she had no ride. No harm judging by today's results (potassium 4.7 mmol/L; creatinine 1.04 mg/dL, eGFR 66, a fall of under 10%). Corrective action: checks scheduled on her clinic days with rides booked in advance, and a home blood draw when no ride can be found |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin, then yearly | Completed today | LDL 80, total cholesterol 154, HDL 46, triglycerides 142 mg/dL |
| Laboratory | ALT, AST and FIB-4 | At baseline, then yearly | Completed today | ALT 26 U/L on atorvastatin; FIB-4 at intake low (0.82) |
| Imaging | Diabetic eye examination (retinal photographs) | At diagnosis, then every 1 to 2 years if no retinopathy | Completed today | No diabetic retinopathy; old left-eye scarring |
| Medication safety | Medicine safety: low blood sugar, sick-day rules, genital infections, cough, swelling, adherence and cost | Every visit | Completed today | No dizziness, cough, swelling or genital itching; all medicines affordable through the discount pharmacy |
| Medication safety | Hepatitis B dose 2 | One month after dose 1 | Completed today | Given after she agreed; series complete |
| Self-management | Diabetes self-management education and support | At diagnosis, then yearly and when needs change | Completed today | First group class attended |
| Survey | Social needs screen (AHC-HRSN) and resources | At intake, then every few months while needs are open | Up to date | SNAP approved; energy assistance pending; transportation the open need |

## Goal progress

- Every examination, test and procedure explained first and done only with her documented agreement, with a chaperone of her choosing, at every visit. In progress; target 2026-10-19. **S**
- Blood pressure below 130/80 mmHg in the clinic and at home within six months. In progress; target 2026-10-19. **S**
- A1c below 7% within six to nine months, without low blood sugar. In progress; target 2026-10-19. **S**
- Urine albumin-to-creatinine ratio lower by at least 30% within six months. In progress; target 2026-10-19. **S**
- Food and utility needs met through benefits, and a dependable way to reach every visit and laboratory test. In progress; target 2026-10-19. **S**
- LDL cholesterol below 70 mg/dL. In progress; target 2026-10-19. **S**

## Guideline basis

- Introduction and Methodology: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- CMID: Clinical Monitoring Intelligence Database, hypertension, diabetes type 2, hyperlipidemia, chronic kidney disease and depression monographs (2026), Aether Forge
- Trauma-Informed Care in Behavioral Health Services (Treatment Improvement Protocol 57) (2014), Substance Abuse and Mental Health Services Administration
- Code of Medical Ethics Opinion 2.1.1: Informed Consent (2026), American Medical Association
- The Accountable Health Communities Health-Related Social Needs Screening Tool (2017), Centers for Medicare & Medicaid Services
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Home readings by phone in four weeks. Review in two months with the A1c, urine albumin, potassium and creatinine, the PHQ-9 and the social needs screen, with the ride booked today. **S**
- Next scheduled visit 2026-07-13: four-month review: A1c, urine albumin, kidney function, mood, social needs, and the metformin dose. **S**
